THERAMEX
FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY
A real world evidence study, presented at the 13th International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders has shown for the first time via direct comparison, that risedronate GR (Actonel® GR) demonstrated superior outcomes for fracture risk reduction in patients with osteoporosis, compared to those who received an immediate release (IR) bisphosphonate.1
The study used healthcare claims data from over 5,000 osteoporosis patients to demonstrate a 17% reduction in incidence of any site fractures for patients taking risedronate GR compared with those taking oral IR bisphosphonates (p<0.05).1 This difference was even more pronounced in spine fractures where a 29% reduction in fracture incidence was seen (p<0.05).1 Time to first fracture was delayed for those receiving risedronate GR, reaching statistical significance at 36 months.1 The incidence of gastric adverse events was broadly similar between the two patient groups.1
Lead study investigator, Dr Friederike Thomasius, comments:
“These data are crucial for all healthcare professionals managing osteoporosis and provide an important insight into real-world evidence. I see patients every day who are struggling with medication compliance due to the inflexible regimes of some bisphosphonates. We know that one in three women over the age of 50 will suffer a fragility fracture that can be life changing. As clinicians we need to carefully consider the options for our patients and what this means for lowering fracture risk.”
Bisphosphonates are recommended by guidelines as a first line treatment but there are a number of restrictions associated with how they are taken, for example, the need to fast overnight before taking and for 30 minutes afterwards.2,3,4 Up to a third of patients treated with bisphosphonates take them with food, which may increase fracture risk.5 risedronate GR is the only oral bisphosphonate which can be taken with food due to its enteric coating.6
Robert Stewart, Chief Executive Officer of Theramex, also shared his thoughts:
“We knew that Actonel GR offered a treatment choice that could remove the variability of compliance experienced with oral immediate release bisphosphonates. We set out to explore the impact of this in a real-world setting. What we found was significantly improved clinical outcomes in fracture risk reduction for patients taking Actonel GR versus oral immediate release bisphosphonates. When we consider bisphosphonates are the first line treatment in a condition affecting 200 million women globally, this is an important finding and completely aligned to our mission at Theramex as a company solely dedicated to improving women’s health.”
Ends
Notes to Editor:
About Osteoporosis
Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.
- It is a significant health issue – affecting ~200 million people worldwide7
- Osteoporosis affects more women than men and risk increases with age8
- After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy8
- One in three women aged over 50 will suffer a fragility fracture9
- Up to a third of patients treated with bisphosphonates (one in three) take their bisphosphonate with food, which may increase fracture risk5
- Hip, spine and wrist fractures are the most common fractures, which have a debilitating impact on daily activities and quality of life9
- After a spine fracture mortality decreased over a 5-year period by up to 16% per year10
- Vertebral fractures can lead to back pain, loss of height, deformity, immobility, QoL, and activities of daily living11,12,13
About treatment
Bisphosphonates are recommended as first-line treatment for osteoporosis by guidelines. Even when taken correctly, only 1% of the dose is absorbed and this can be impaired by food, calcium, iron, coffee, tea and orange juice.14,15 Most patients take their bisphosphonates before breakfast as there are a number of restrictions when taking oral bisphosphonates, which can be a major inconvenience. Patients must:2,3,4
- Fast overnight before taking the medication
- Fast for 30 minutes after taking the medication (before having breakfast)
- Stay upright for 30 minutes after taking the medication
- Take with a glass of water (not juice or coffee)
- Take separately from other medications
Real-world evidence indicates that many patients do not comply with the complex dosing instructions.5 Poor compliance can result in suboptimal efficacy and 45% increased risk of fractures.16
About Risedronate Gastric Resistant (GR) (Actonel®)
Risedronate GR is an oral bisphosphonate which has flexible administration requirements for patients.6 Due to its gastro-resistant enteric coating risedronate GR can bypass the stomach and is absorbed in the small intestine, where the absorption of a bisphosphonate is most important.17 Risedronate GR, therefore, provides 2-4 times higher bioavailability than oral IR bisphosphonates when taken with food.17 Risedronate GR is the only oral bisphosphonate which can be taken with food and, therefore, can be taken immediately after breakfast.6 The flexibility offered by risedronate GR dosing offers a convenient option for patients who may struggle with more restrictive treatment dosing requirements. Risedronate GR was approved by the European Medicines Agency (EMA), as a treatment for patients with Osteoporosis, in October 2016.
About the study1
This retrospective, observational analysis of US healthcare database claims compared the fracture rate and economic burden in female osteoporosis patients who received risedronate GR (n=2,726) with those treated with immediate release bisphosphonates (n=2,726).1 The two cohorts were matched based on patient characteristics and history.1
All patients had ≥1 prescription fill for an oral bisphosphonate, had ≥1 medical claim associated with ≥6 months of continuous eligibility for both pharmacy and medical benefits 6 months prior to the observational period of this study. Patients with a history of Paget’s disease or specific malignancies were excluded from the study.1
Patients without a treatment switch were observed for ≥2 years from the first study-related prescription.1 New fracture events were identified from relevant diagnosis codes from medical claims. In the case of recurrent fracture, the claim was required to occur ≥30 days after the previous fracture claim at distinct skeletal sites and ≥90 days apart if occurring at the same site. Healthcare resource use was also compared.1
About Theramex
For further information on Theramex, please follow this link to the company About Us section of our website: https://www.theramex.com
References:
- Thomasius, F. et al. Abstract presented at 13th International Conference on, Osteoporosis, Arthritis and Musculoskeletal Disorders, April 23-24, Dubai 2021
- Warner Chilcott UK Ltd. Actonel 5 mg SmPC
- Accord Healthcare Ltd. Alendronic acid 10 mg SmPC
- Consilient Health Ltd. Ibandronic acid 50 mg SmPC
- Vytrisalova et al CLIMACTERIC;18:608–616(2015)
- Theramex Ltd. Risedronate sodium gastro-resistant SmPC
- Noh JY et al. Int J Mol Sci;21,7623(2020)
- IOF. Risk Factors. Last accessed:April 2021
- IOF Compendium of Osteoporosis. Last accessed:April 2021
- Johnell O et al. Osteoporos Int;15,38-42(2004)
- Nevitt MC et al. Ann Intern Med;128:793(1998)
- Lips P et al. Osteoporos Int;10:150(1999)
- Tosteson AN et al. Osteoporos Int ;2:1042(2001)
- Lin J. Bone;18:75–85(1996)
- Kanis JA et al. Osteoporosis Int;30:3–44(2019)
- Penning-van Beest F.J.A et al. Osteoporos Int;19(4): 511-517(2008)
- Pazianas M, et al. Ther Clin Risk Manag;9:395–402(2013)
Job number:ACTOGR_HQ_PRESSR_003521
Date of preparation:April 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Catch the Best Prime Day Offers on Smart Home Must-Haves: EZVIZ Rolls Out Jaw-Dropping Deals on Tried-and-True Cameras and Entryway Innovations for Everyday Peace of Mind8.7.2025 11:30:00 CEST | Press release
This Prime Day, EZVIZ, an internationally trusted name in smart home security, introduces a handpicked selection of exclusive offers that protect homes from the very first point of contact. For households that value safety around the home and especially at the very threshold, this is a moment to invest in home security that is as advanced as it is effortless. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702338311/en/ From 8 to 11 July, homeowners can seize the window on EZVIZ Prime Day deals on Amazon UK, featuring EZVIZ’s best-loved smart cameras, expertly bundled packages, and a complete range of entry products. These limited-time savings offer a rare opportunity to elevate home protection, no matter for a bustling city apartment or a sprawling family residence. Here are some top-rated deals: CP3 Pro Video Doorbell with solar panel – now £49.98, was £79.99 An intelligent welcome with built-in protection. Powered by an
CapVest and Parquest Agree Terms on IPN’s Acquisition of Sopral8.7.2025 10:00:00 CEST | Press release
Inspired Pet Nutrition (“IPN”), the fast-growing pet food company controlled by CapVest Partners LLP (“CapVest”), and Parquest, a leading investment firm, have agreed terms on the acquisition of Sopral, a prominent branded pet food platform serving the European market, with manufacturing operations based in France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708134461/en/ Sopral products The transaction is subject to customary regulatory approvals and closing conditions. Financial terms have not been disclosed. Based in Pléchâtel, Brittany, France, Sopral is a leading manufacturer of branded premium dry petfood with a comprehensive range of high-quality nutritional solutions, including Pro-Nutrition Prestige, Pure Life and Protect brands. Sopral has a strong footprint and reputation in France and a fast growing online and international market presence in over 50 countries around the world. Employing over 130 people, th
Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release
At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release
Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime
Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release
Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom